ArticleInfection and immunity2004
Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Engaging Broader Stakeholders to Accelerate Group AVaccines · 2025Review
- Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasiveFrontiers in immunology · 2024Article
- Novel virulence factor Cba induces antibody-dependent enhancement (ADE) ofFrontiers in cellular and infection microbiology · 2023Article
- Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.Cureus · 2022Review
- Article
- Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.Vaccines · 2019Review
- Contribution of cryptic epitopes in designing a group A streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Spatiotemporal epidemiology of scarlet fever in Jiangsu Province, China, 2005-2015.BMC infectious diseases · 2017Article
- Article
- Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Clinical microbiology reviews · 2014Review
- Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Current infectious disease reports · 2012Article
- Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor.The Journal of infectious diseases · 2011Article
- Adhesion determinants of the Streptococcus species.Microbial biotechnology · 2010Review
- Flexible architecture of the Streptococcus pyogenes FCT genome region: finally the clue for understanding purulent skin diseases and long-term persistence?Journal of bacteriology · 2007Article
- Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs.Infection and immunity · 2006Article
- Biological basis for syphilis.Clinical microbiology reviews · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibronectin binding protein F1 (Sfb1) of Streptococcus pyogenes (group A streptococcus [GAS]) is a well-characterized adhesin that has been shown to induce protection in mice against a lethal intranasal GAS challenge after intranasal immunization with cholera toxin B subunit (CTB) as adjuvant. With a murine skin infection model, we have shown that Sfb1/CTB vaccination neither elicits opsonizing antibodies nor prevents systemic bacterial growth and dissemination to internal organs after a subcutaneous GAS challenge. These results indicate that an Sfb1-based vaccine should be complemented with additional protective antigens in order to be used in areas such as the tropical north of Australia, where the skin is the primary route of entry for invasive streptococcal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.